GSK to spend up to $3.3 bln on Affinivax to boost vaccines roster
dailymail.co.uk
news
2022-05-31 06:28:00

By Reuters Published: 02:28 EDT, 31 May 2022 | Updated: 04:17 EDT, 31 May 2022 By Pushkala Aripaka May 31 (Reuters) - GSK on Tuesday agreed to buy U.S. biotech Affinivax for up to $3.3 billion, its second major deal in two months, giving the British pharmaceutical giant access to the company's roster of next-generation vaccines. GSK, one of the world's major vaccine makers, has been under pressure to shore up its pharmaceutical pipeline ahead of the separation in July of its consumer business, home to brands such as Sensodyne toothpaste and Advil painkillers.
